BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 15642967)

  • 21. [Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene].
    Djaman AJ; Basco LK; Mazabraud A
    Sante; 2002; 12(4):363-7. PubMed ID: 12626289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
    Tinto H; Ouédraogo JB; Zongo I; van Overmeir C; van Marck E; Guiguemdé TR; D'Alessandro U
    Am J Trop Med Hyg; 2007 Apr; 76(4):608-13. PubMed ID: 17426157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.
    Schönfeld M; Barreto Miranda I; Schunk M; Maduhu I; Maboko L; Hoelscher M; Berens-Riha N; Kitua A; Löscher T
    Malar J; 2007 Jan; 6():2. PubMed ID: 17224049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short report: molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo.
    Cohuet S; Bonnet M; Van Herp M; Van Overmeir C; D'Alessandro U; Guthmann JP
    Am J Trop Med Hyg; 2006 Jul; 75(1):152-4. PubMed ID: 16837723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.
    Barnes KI; Little F; Mabuza A; Mngomezulu N; Govere J; Durrheim D; Roper C; Watkins B; White NJ
    J Infect Dis; 2008 Jun; 197(11):1605-13. PubMed ID: 18471066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia.
    Hailemeskel E; Kassa M; Taddesse G; Mohammed H; Woyessa A; Tasew G; Sleshi M; Kebede A; Petros B
    Acta Trop; 2013 Dec; 128(3):636-41. PubMed ID: 24055717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
    Toma H; Imada Y; Vannachone B; Miyagi M; Kobayashi J; Uechi G; Pethuvang R; Manivong K; Phompida S; Sato Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):602-4. PubMed ID: 16124424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
    Méndez F; Herrera S; Murrain B; Gutiérrez A; Moreno LA; Manzano M; Muñoz A; Plowe CV
    Am J Trop Med Hyg; 2007 Sep; 77(3):438-43. PubMed ID: 17827356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
    Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
    Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda.
    Sendagire H; Kyabayinze D; Swedberg G; Kironde F
    Trop Med Int Health; 2005 Jun; 10(6):537-43. PubMed ID: 15941416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.
    Francis D; Nsobya SL; Talisuna A; Yeka A; Kamya MR; Machekano R; Dokomajilar C; Rosenthal PJ; Dorsey G
    J Infect Dis; 2006 Apr; 193(7):978-86. PubMed ID: 16518760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea.
    Mita T; Kaneko A; Hwaihwanje I; Tsukahara T; Takahashi N; Osawa H; Tanabe K; Kobayakawa T; Björkman A
    Infect Genet Evol; 2006 Nov; 6(6):447-52. PubMed ID: 16600696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
    Basco LK; Tahar R; Keundjian A; Ringwald P
    J Infect Dis; 2000 Aug; 182(2):624-8. PubMed ID: 10915101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi.
    Nkhoma S; Molyneux M; Ward S
    Acta Trop; 2007 May; 102(2):138-42. PubMed ID: 17544355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets.
    Alifrangis M; Lemnge MM; Rønn AM; Segeja MD; Magesa SM; Khalil IF; Bygbjerg IC
    Am J Trop Med Hyg; 2003 Sep; 69(3):238-43. PubMed ID: 14628937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use.
    Nsimba B; Jafari-Guemouri S; Malonga DA; Mouata AM; Kiori J; Louya F; Yocka D; Malanda M; Durand R; Le Bras J
    Trop Med Int Health; 2005 Oct; 10(10):1030-7. PubMed ID: 16185238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
    Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T
    Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative.
    Sendagire H; Kaddumukasa M; Ndagire D; Aguttu C; Nassejje M; Pettersson M; Swedberg G; Kironde F
    Acta Trop; 2005 Sep; 95(3):172-82. PubMed ID: 16018959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon.
    Bouyou-Akotet MK; Mawili-Mboumba DP; Tchantchou Tde D; Kombila M
    J Antimicrob Chemother; 2010 Mar; 65(3):438-41. PubMed ID: 20053688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ordered accumulation of mutations conferring resistance to sulfadoxine-pyrimethamine in the Plasmodium falciparum parasite.
    Mita T; Ohashi J; Venkatesan M; Marma AS; Nakamura M; Plowe CV; Tanabe K
    J Infect Dis; 2014 Jan; 209(1):130-9. PubMed ID: 23922363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.